Pharmaceutical Care for A Patient with Pneumocystis Jirovecii Pneumonia Secondary to Immune-mediated Colitis Caused by Serplulimab
10.3870/j.issn.1004-0781.2025.08.023
- VernacularTitle:1例斯鲁利单抗致免疫介导结肠炎继发耶氏肺孢子肺炎患者的药学监护
- Author:
Zhongliang TANG
1
;
Qian REN
;
Ying YANG
;
Jianping ZHANG
Author Information
1. 兰州大学第一医院药剂科,兰州 730000;甘肃省第三人民医院药剂科,兰州 730000
- Publication Type:Journal Article
- Keywords:
Immune checkpoint inhibitors;
Colitis;
Pneumocystis jirovecii pneumonia;
Fecal microbiota transplantation;
Pharmaceutical care
- From:
Herald of Medicine
2025;44(8):1342-1346
- CountryChina
- Language:Chinese
-
Abstract:
Objective To summarize the role of clinical pharmacists in pharmaceutical care in the treatment of patients with pneumocystis jirovecii pneumonia secondary to immune-mediated colitis.Methods The association of immune-mediated colitis induced by serplulimab was evaluated by clinical pharmacist,anti-infective regimen for pneumocystis jirovecii pneumonia was put forward,addressed concerns regarding the impact of trimethoprim/sulfamethoxazole on the efficacy of fecal microbiota transplantation,pharmaceutical care for whole therapeutic process of the patient was monitored.Results Through pharmaceutical care and collaborating with physicians,the patient's pneumocystis jirovecii pneumonia was significantly improved,and the clinical and endoscopic remission of immune-mediated colitis after two fecal microbiota transplantation were achieved.Conclusion To ensure the safety and effectiveness of immune-mediated colitis and pneumocystis jirovecii pneumonia for patients,clinical pharmacists should play the role of participation and pharmaceutical care.
